Clinical ResearchImpact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C☆,☆☆
Section snippets
Materials and methods
The individual data from 4 randomized trials of PEG-interferon alfa-2b alone (Pegintron, Schering Plough, Kenilworth, NJ),8 or in combination with ribavirin,11 or of the combination interferon alfa-2b and ribavirin (Rebetron, Schering Plough)12, 13 were obtained. Patients with serologic confirmation of chronic hepatitis C were included if they had both pretreatment and posttreatment liver biopsies. Patients were excluded if they had HBV or human immunodeficiency virus infection, a daily alcohol
Progression of fibrosis was analyzed by 3 methods
First, we compared the impact of the different treatment regimens on the percentage of patients who improve by at least 1 fibrosis stage, remained stable, or worsened by at least 1 stage.
Secondly, we compared the different treatment regimens according to the fibrosis progression rates per year before and after treatment. These estimates have been extensively detailed and validated previously.2, 6, 19
The fibrosis progression rate after treatment was defined as the ratio between the difference in
Results
Of the 4493 naive patients enrolled in the 4 trials, 3010 had paired biopsies available with a 20-month mean duration between the biopsies (Table 1). There were no statistically significant differences between the original population and the population of patients with paired biopsies included in this analysis. At baseline, 2243 patients had no significant fibrosis (75%) and 767 significant fibrosis (25%), 673 (22%) had no significant activity, and 2337 (78%) significant activity. The mean
Discussion
This overview of 4 pivotal randomized trials has permitted us to assess the incremental benefit of 10 different regimens on the histological features of patients infected with hepatitis C virus. These regimens given for 24 or 48 weeks allowed us to observe an improvement of necrosis and inflammation grades and a reduction of fibrosis progression at least during the 2 years' histological follow-up. This analysis has also demonstrated that the histological improvement was related both to the
Acknowledgements
The authors thank all the investigators of PEG-FIBROSIS project including the investigators of the randomized trials.
References (28)
- et al.
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Lancet
(1997) - et al.
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view
Gastroenterology
(1999) - et al.
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
Hepatology
(2000) - et al.
A randomised, double blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
Hepatology
(2001) - et al.
PEG-Interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C
Lancet
(2001) - et al.
Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
Lancet
(1998) - et al.
An algorithm for the grading of activity in chronic hepatitis C
Hepatology
(1996) - et al.
Standardization of hepatitis C virus RNA quantification
Hepatology
(2000) - et al.
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
J Hepatol
(2001) - et al.
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
Gastroenterology
(1999)
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
Lancet
Liver fibrosis in overweight patients
Gastroenterology
Hepatitis C: global prevalence
Wkly Epidemiol Rec
Rising incidence of hepatocellular carcinoma in the United States
N Engl J Med
Cited by (0)
- ☆
Address requests for reprints to: Professeur Thierry Poynard, Service d'Hépato-Gastroentérologie Groupe Hospitalier Pitié-Salpêtrière 47-83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France. e-mail: [email protected].
- ☆☆
Supported by research grants from Schering Plough Research Institute, Kenilworth, New Jersey, by Direction de la Recherche Clinique Assistance Publique Hôpitaux de Paris, by Association pour la Recherche contre le Cancer, and by Association pour la Recherche sur les Maladies Hepatiques Viroles, Paris, France.